Biotech Values

[ghmm]

OCRX:

I'm currently traveling and limited access to things. Here is my summary bull case.

1) IV product (OCR-002) should have Phase 2 date Q1 '17
1a) Ravicti had positive P2 stopping future HE (Hyperion not pursuing since approved in much higher priced rare disorder). Comparable dose.
1b) April 2015 interim (safety, futility, overwhelming efficacy, sample size adjustment to maintain 80% power) resulted in sample size increase to 230 and company estimates that would indicate saw 1.5 - 2 day improvement.
2) Oral formulation of OCR-002 should have data Q4 '16 (single dose) and 1H '17 (multi dose)
3) Cash through 2017 (35M as of 6/30/16) have some debt though and active ATM
4) Estimated market opp. (per company) 600-700M IV, Oral 800-900M.
5) Have full worldwide rights
I see they have their August Presentation: http://files.shareholder.com/downloads/ABEA-5YQ58G/2761847900x0x904351/BE1982B0-982D-4689-9A33-5ECE37FB9B94/Ocera_Presentation_Aug_2016.pdf